anti-V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1) Antibodies

VTCN1 encodes a protein belonging to the B7 costimulatory protein family. Additionally we are shipping VTCN1 Proteins (46) and VTCN1 Kits (21) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
VTCN1 242122 Q7TSP5
VTCN1 79679 Q7Z7D3
VTCN1 295322 Q501W4
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-VTCN1 Antibodies at antibodies-online.com

Showing 10 out of 172 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Delivery Price Details
Human Goat Un-conjugated ELISA, WB ABIN334524 (0.3µg/ml) staining of Human Spleen lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence. 100 μg 6 to 7 Days
$429.84
Details
Human Rabbit Un-conjugated ELISA, WB 0.1 mg 2 to 3 Days
$360.00
Details
Human Rabbit Un-conjugated EIA, WB Western blot analysis of VTCN1 Antibody (Center) in T47D cell line lysates (35 µg/lane). VTCN1 (arrow) was detected using the purified Pab. 0.4 mL 6 to 8 Days
$484.00
Details
Human Rabbit Un-conjugated FACS, IF (p), IHC (p), WB Formalin-fixed and paraffin embedded human thyroid carcinoma labeled Anti-B7H4 Polyclonal Antibody, Unconjugated (ABIN671736) at 1:200, followed by conjugation to the secondary antibody and DAB staining Formalin-fixed and paraffin embedded human gastric carcinoma labeled Anti-B7H4 Polyclonal Antibody, Unconjugated (ABIN671736) at 1:200, followed by conjugation to the secondary antibody and DAB staining 100 μL 3 to 7 Days
$329.45
Details
Bat Goat Un-conjugated ELISA, WB 100 μg 11 to 14 Days
$610.50
Details
Human Goat Un-conjugated ELISA, WB 100 μg 11 to 14 Days
$610.50
Details
Human Rabbit Un-conjugated IHC (p), ELISA Human B7-H4/Vtcn1/B7S1 Immunohistochemistry(IHC) 7760 Human B7-H4/Vtcn1/B7S1 Immunohistochemistry(IHC) 7761 100 μL 14 to 16 Days
$247.82
Details
Human Mouse PE FACS, IHC, IHC (fro), IHC (p) 100 Tests 11 to 14 Days
$610.50
Details
Human Rabbit Un-conjugated ELISA, IHC, IHC (p), WB Anti-VTCN1 / B7-H4 antibody IHC staining of human colon. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 20 ug/ml. This image was taken for the unconjugated form of this p ... 100 μg 11 to 14 Days
$845.17
Details
Human Rabbit Un-conjugated ELISA, WB Western blot analysis of VTCN1 using HT29 whole  lysates. Western blot analysis of extracts from rat liver, using VTCN1 Antibody. 100 μL 11 to 12 Days
$390.77
Details

Top referenced anti-VTCN1 Antibodies

  1. Human Polyclonal VTCN1 Primary Antibody for CyTOF, FACS - ABIN4900129 : Radichev, Maneva-Radicheva, Amatya, Salehi, Parker, Ellefson, Burn, Savinov: Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes. in Journal of immunology (Baltimore, Md. : 1950) 2016 (PubMed)
    Show all 3 Pubmed References

  2. Human Monoclonal VTCN1 Primary Antibody for FACS - ABIN2688846 : Sica, Choi, Zhu, Tamada, Wang, Tamura, Chapoval, Flies, Bajorath, Chen: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. in Immunity 2003 (PubMed)
    Show all 3 Pubmed References

  3. Human Polyclonal VTCN1 Primary Antibody for IHC, IHC (p) - ABIN4282807 : Xu, Zhang, Zhang, Liu, Yin, Liu, Zhuo: Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. in Oncology letters 2016 (PubMed)
    Show all 2 Pubmed References

  4. Mouse (Murine) Polyclonal VTCN1 Primary Antibody for FACS, WB - ABIN4900128 : Lee, Scandiuzzi, Ray, Wei, Hofmeyer, Abadi, Loke, Lin, Yuan, Serreze, Allison, Zang: B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. in Journal of immunology (Baltimore, Md. : 1950) 2012 (PubMed)
    Show all 2 Pubmed References

  5. Human Polyclonal VTCN1 Primary Antibody for ELISA, WB - ABIN451629 : Krambeck, Thompson, Dong, Lohse, Park, Kuntz, Leibovich, Blute, Cheville, Kwon: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. in Proceedings of the National Academy of Sciences of the United States of America 2006 (PubMed)

  6. Human Polyclonal VTCN1 Primary Antibody for FACS, IF (p) - ABIN671736 : Maskey, Li, Hu, Xu, Peng, Yu, Cao, Chen, Li, Yang: Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis. in Tumour biology 2014 (PubMed)

  7. Human Monoclonal VTCN1 Primary Antibody for IHC (fro), FACS - ABIN2477564 : van de Ven, van den Hout, Lindenberg, Sluijter, van Leeuwen, Lougheed, Meijer, van den Tol, Scheper, de Gruijl: Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. in Blood 2011 (PubMed)

More Antibodies against VTCN1 Interaction Partners

Mouse (Murine) V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1) interaction partners

  1. study presents first evidence that B7-H4 acts as a tumor suppressor through PTEN/AKT/HIF-1alpha/RCOR2/RUNX1 pathways to promote the differentiation of leukemia-initiating cells but does not impair the normal functions of hematopoietic stem cells

  2. B7S1 initiates dysfunction of tumor-infiltrating CD8+ T cells and may be targeted for cancer immunotherapy.

  3. this study shows that B7-H4 knockout hosts mount greater tumor-associated anti-tumor T cell responses and display reduced tumors

  4. Results highlight an importance of VTCN1 stabilization on cell surfaces for the restoration of altered balance of immune control during T1D.

  5. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer

  6. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.

  7. that B7x can modulate kidney damage in autoimmune diseases including lupus nephritis and anti-glomerular basement membrane disease

  8. B7-H4 can inhibit both antitumor T cells and protumor myeloid-derived suppressor cells (

  9. The endogenous expression of B7-H4 in donor beta cells from transgenic mice prolongs islet allograft survival, confirming the negative role of B7-H4 in regulating alloreactive T-cell responses.

  10. Local overexpression of B7x on pancreatic beta cells is sufficient to abolish CD8 T cell-induced diabetes.

  11. An enhanced T cell response contributes to reduced lethality in a pulmonary infection model with Streptococcus pneumoniae.

  12. B7-H4 expression may influence the outcome of T-cell tumor cell interactions. Tumor-associated macrophage induced membrane-bound B7-H4 on lung cancer cell represents a novel mechanism by which lung cancer cells evade immune recognition and destruction.

  13. Overexpression of B7-H4 was shown in tumor infiltrated dendritic cells.

  14. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity.

  15. intact recipient, but not donor, B7-H4 is essential for prolongation of allograft survival by blocking CD28/CTLA4:B7 pathway using CTLA4-Ig.

  16. studies reveal a novel role for activated hepatic stellate cells in the attenuation of intrahepatic T cell responses by way of expression of the coinhibitory molecule B7-H4.

  17. May participate in negative regulation of cell-mediated immunity in peripheral tissues

  18. novel negative costimulator and regulates the threshold of T cell activation

  19. Genomic DNA of mouse B7-H4 is mapped on chromosome 3 comprised of six exons and five introns spanning 66 kb.

  20. These results suggest that B7-H4 is one of multiple negative cosignaling molecules that collectively provide a fine-tuning mechanism for T-cell-mediated immune responses.

Human V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1) interaction partners

  1. The expressions of CD24, B7-H4 and PCNA have correlations with the occurrence, development, invasion and metastasis of ovarian cancer, and the combined detection may have clinical guiding significance for early diagnosis of ovarian cancer and screening of high-risk patients.

  2. this study shows that soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia

  3. The expression of B7-H3 and B7-H4 favored an immunosuppressive microenvironment by promoting the production of IL-10 and TGFB1, thereby resulting in progression of cervical carcinogenesis.

  4. Expression of B7H3 and B7H4 is closely corelated with clinicopathological parameters and prognosis of patients with T-LBL/ALL, suggesting that B7H3 and B7H4 expression play an important role in the development of T-LBL/ALL.

  5. B7-H4Ig binds to Sema3a, which acts as a functional bridge to stimulate an Nrp-1/Plexin A4 heterodimer.

  6. B7H4-expressing cancer cells also expressed known cancer stemness proteins (Sox9, LSD1, Oct4, and LGR5)

  7. Increased B7 protein expression by infiltrating immune cells was associated with disease progression, and specifically, the level of B7-H3 expression and localization of B7-H4 expression differed significantly among different stages of gastric carcinogenesis.

  8. None of the genotype distributions showed a significant difference from the control group for the rs10801935 polymorphism. We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma.

  9. B7-H4/NF-kappaB signaling is involved in the EMT and invasion of bladder cancer cells.

  10. The aim of the present work was to evaluate the effectiveness of anti-B7-H4-scFv-CH3 against tumors in vitro and in vivo. ScFv can inhibit signaling pathways to improve immunity by binding with the T lymphocyte negative co-stimulatory factor B7-H4.

  11. High B7-H4 expression is associated with phyllodes tumors.

  12. Studies suggest that V-set domain containing T cell activation inhibitor 1 protein (B7S1) may represent a very promising candidate to be targeted to treat various tumors.

  13. Human Immunodeficiency virus type-1 myeloid derived suppressor cells inhibit cytomegalovirus inflammation through IL-27 and B7-H4.

  14. High B7-H4 expression is associated with glioblastoma.

  15. Serum B7-H4 detection, either alone or in combination with carbohydrate antigen 125, has an acceptable value in the diagnosis of OC.

  16. the findings of this study suggested that B7-H4 may have the potential to be a valuable prognostic marker and a target for individualized therapies for gastric cancer

  17. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.

  18. B7-H3 protein is expressed in the majority of NSCLCs and is associated with smoking history. High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas. Coexpression of B7-H3 with PD-L1 and B7-H4 is relatively low, suggesting a nonredundant biological role of these targets.

  19. When compared to early-stage lung adenocarcinoma, metastatic pleural adenocarcinoma possessed higher level of nuclei membranous B7-H4 and lower cytoplasmic B7-H4 expression.

  20. The decrease of B7-H4 expression in salivary glands of Sjogren's syndrome patients contributes to the defect of negatively regulating the inflammation caused by CD4(+) T cells.

VTCN1 Antigen Profile

Protein Summary

This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this family are present on the surface of antigen-presenting cells and interact with ligand bound to receptors on the surface of T cells. Studies have shown that high levels of the encoded protein has been correlated with tumor progression. A pseudogene of this gene is located on chromosome 20. Multiple transcript variants encoding different isoforms have been found for this gene.

Gene names and symbols associated with VTCN1

  • V set domain containing T cell activation inhibitor 1 L homeolog (vtcn1.L) antibody
  • V-set domain containing T cell activation inhibitor 1 (VTCN1) antibody
  • V-set domain containing T-cell activation inhibitor 1 (VTCN1) antibody
  • V set domain containing T cell activation inhibitor 1 (vtcn1) antibody
  • V-set domain containing T cell activation inhibitor 1 (Vtcn1) antibody
  • B7-H4 antibody
  • B7h.5 antibody
  • B7H4 antibody
  • B7S1 antibody
  • B7X antibody
  • BC032925 antibody
  • PRO1291 antibody
  • RGD1311204 antibody
  • VCTN1 antibody

Protein level used designations for VTCN1

V-set domain-containing T-cell activation inhibitor 1 , V-set domain containing T cell activation inhibitor 1 , V-set domain containing T-cell activation inhibitor 1 , immune costimulatory protein B7-H4 , t cell costimulatory molecule B7x , B7 family member, H4 , B7 superfamily member 1 , T cell costimulatory molecule B7x , T-cell costimulatory molecule B7x

GENE ID SPECIES
379070 Xenopus laevis
418323 Gallus gallus
469433 Pan troglodytes
493551 Xenopus (Silurana) tropicalis
242122 Mus musculus
79679 Homo sapiens
295322 Rattus norvegicus
Selected quality suppliers for anti-VTCN1 (VTCN1) Antibodies
Did you look for something else?